https://www.selleckchem.com/pr....oducts/methyl-b-cycl
6% (CI 88.2%, 94.3%) in patients who received the SpiderFX filter ( =0.434). The lower limit of 86.7% freedom from major adverse event rate in the Emboshield NAV6 group was above the performance goal of 83% ( 0.0008). There were no significant clinical outcome differences between Emboshield NAV6 and SpiderFX EPD filters in the treatment of lower extremities. This evaluation indicates the safety and efficacy to use either filter device to treat PAD patients with lower extremity lesions. There were no significant clinic
Synes godt om
Kommentar
Del
